{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:45:23Z","timestamp":1789015523883,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EI 1185\/1-1"],"award-info":[{"award-number":["EI 1185\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Total body irradiation (TBI)-based conditioning is associated with superior leukemia-free survival in children with ALL undergoing HSCT. However, the risk for subsequent malignant neoplasms (SMN) remains a significant concern. We analyzed 705 pediatric patients enrolled in the prospective ALL-SCT-BFM-2003 trial and its subsequent registry. Patients &gt;2 years received conditioning with TBI 12\u2009Gy\/etoposide (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009558) and children \u22642 years of age or with contraindications for TBI received busulfan\/cyclophosphamide\/etoposide (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009110). The 5- and 10-year cumulative incidence of SMN was 0.02\u2009\u00b1\u20090.01 and 0.13\u2009\u00b1\u20090.03, respectively. In total, 39 SMN (34 solid tumors, 5 MDS\/AML) were diagnosed in 33 patients at a median of 5.8 years (1.7\u201313.4), exclusively in the TBI group. Of 33 affected patients, 21 (64%) are alive at a median follow-up of 5.1 years (0\u20139.9) after diagnosis of their first SMN. In univariate analysis, neither age at HSCT, donor type, acute GVHD, chronic GVHD, nor CMV constituted a significant risk factor for SMN. The only significant risk factor was TBI versus non-TBI based conditioning. This analysis confirms and quantifies the increased risk of SMN in children with ALL after conditioning with TBI. Future strategies to avoid TBI will need careful tailoring within prospective, controlled studies to prevent unfavorable outcomes.\n                  <\/jats:p>","DOI":"10.1038\/s41375-022-01693-z","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T14:03:55Z","timestamp":1662991435000},"page":"2567-2576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL \u2013 long-term follow-up from the prospective ALL-SCT 2003 trial"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2256-6633","authenticated-orcid":false,"given":"Anna","family":"Eichinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Poetschger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Glogova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-0265","authenticated-orcid":false,"given":"Peter","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Beier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-829X","authenticated-orcid":false,"given":"Birgit","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl-Friedrich","family":"Classen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7064-8556","authenticated-orcid":false,"given":"Alexander","family":"Claviez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Corbacioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-4893","authenticated-orcid":false,"given":"Hedwig E.","family":"Deubzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1862-0075","authenticated-orcid":false,"given":"Bernd","family":"Gruhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3261-1186","authenticated-orcid":false,"given":"Tayfun","family":"G\u00fcng\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinan","family":"Kafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn-Sven","family":"K\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-2142","authenticated-orcid":false,"given":"Peter","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern Soenke","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-0628","authenticated-orcid":false,"given":"Roland","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7477-6632","authenticated-orcid":false,"given":"Ingo","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Gerhardt","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7798-7996","authenticated-orcid":false,"given":"Ansgar","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stachel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6086-130X","authenticated-orcid":false,"given":"Brigitte","family":"Strahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Wawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0369-8515","authenticated-orcid":false,"given":"Christina","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9143-3263","authenticated-orcid":false,"given":"Michael H.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"1693_CR1","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood-2015-09-670729","volume":"127","author":"A Moricke","year":"2016","unstructured":"Moricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127:2101\u201312.","journal-title":"Blood"},{"key":"1693_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2019.09.004","volume":"122","author":"AM Testi","year":"2019","unstructured":"Testi AM, Attarbaschi A, Valsecchi MG, Moricke A, Cario G, Niggli F, et al. Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15\u201317 years: long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. Eur J Cancer. 2019;122:61\u201371.","journal-title":"Eur J Cancer"},{"key":"1693_CR3","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"CH Pui","year":"2015","unstructured":"Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938\u201348.","journal-title":"J Clin Oncol"},{"key":"1693_CR4","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/s41375-019-0670-y","volume":"34","author":"A Attarbaschi","year":"2020","unstructured":"Attarbaschi A, Mann G, Zimmermann M, Bader P, Barisone E, Basso G, et al. Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia. 2020;34:1694\u2013700.","journal-title":"Leukemia"},{"key":"1693_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","volume":"39","author":"C Peters","year":"2021","unstructured":"Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority Phase III Study. J Clin Oncol. 2021;39:295\u2013307.","journal-title":"J Clin Oncol"},{"key":"1693_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","volume":"33","author":"C Peters","year":"2015","unstructured":"Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015;33:1265\u201374.","journal-title":"J Clin Oncol"},{"key":"1693_CR7","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.bbmt.2018.05.009","volume":"24","author":"JH Dalle","year":"2018","unstructured":"Dalle JH, Balduzzi A, Bader P, Lankester A, Yaniv I, Wachowiak J, et al. Allogeneic stem cell transplantation from HLA-mismatched donors for pediatric patients with acute lymphoblastic leukemia treated according to the 2003 BFM and 2007 international BFM studies: impact of disease risk on outcomes. Biol Blood Marrow Transpl. 2018;24:1848\u201355.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1693_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/bmt.2009.92","volume":"45","author":"D Bresters","year":"2010","unstructured":"Bresters D, van Gils IC, Kollen WJ, Ball LM, Oostdijk W, van der Bom JG, et al. High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. Bone Marrow Transpl. 2010;45:79\u201385.","journal-title":"Bone Marrow Transpl"},{"key":"1693_CR9","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1038\/s41409-020-0806-8","volume":"55","author":"F Saglio","year":"2020","unstructured":"Saglio F, Zecca M, Pagliara D, Giorgiani G, Balduzzi A, Calore E, et al. Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. Bone Marrow Transpl. 2020;55:1918\u201327.","journal-title":"Bone Marrow Transpl"},{"key":"1693_CR10","doi-asserted-by":"publisher","first-page":"e182453","DOI":"10.1001\/jamaoncol.2018.2453","volume":"4","author":"AS Holmqvist","year":"2018","unstructured":"Holmqvist AS, Chen Y, Wu J, Battles K, Bhatia R, Francisco L, et al. Assessment of late mortality risk after allogeneic blood or marrow transplantation performed in childhood. JAMA Oncol. 2018;4:e182453.","journal-title":"JAMA Oncol"},{"key":"1693_CR11","first-page":"146","volume":"2","author":"S Bomken","year":"2015","unstructured":"Bomken S, Skinner R. Secondary malignant neoplasms following haematopoietic stem cell transplantation in childhood. Child (Basel). 2015;2:146\u201373.","journal-title":"Child (Basel)"},{"key":"1693_CR12","doi-asserted-by":"publisher","first-page":"100783","DOI":"10.1016\/j.blre.2020.100783","volume":"48","author":"MS Alabdaljabar","year":"2021","unstructured":"Alabdaljabar MS, Muhsen IN, Knight JM, Syrjala KL, Hashmi SK. Free of malignancy but not of fears: a closer look at Damocles syndrome in survivors of hematologic malignancies. Blood Rev. 2021;48:100783.","journal-title":"Blood Rev"},{"key":"1693_CR13","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/s41409-020-0782-z","volume":"55","author":"G Di Giuseppe","year":"2020","unstructured":"Di Giuseppe G, Thacker N, Schechter T, Pole JD. Anxiety, depression, and mental health-related quality of life in survivors of pediatric allogeneic hematopoietic stem cell transplantation: a systematic review. Bone Marrow Transpl. 2020;55:1240\u201354.","journal-title":"Bone Marrow Transpl"},{"key":"1693_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/bmt.2010.280","volume":"46","author":"CE Hill-Kayser","year":"2011","unstructured":"Hill-Kayser CE, Plastaras JP, Tochner Z, Glatstein E. TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions. Bone Marrow Transpl. 2011;46:475\u201384.","journal-title":"Bone Marrow Transpl"},{"key":"1693_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.critrevonc.2018.01.011","volume":"123","author":"A Paix","year":"2018","unstructured":"Paix A, Antoni D, Waissi W, Ledoux MP, Bilger K, Fornecker L, et al. Total body irradiation in allogeneic bone marrow transplantation conditioning regimens: a review. Crit Rev Oncol Hematol. 2018;123:138\u201348.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1693_CR16","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/bmt.2015.63","volume":"50","author":"Y Inamoto","year":"2015","unstructured":"Inamoto Y, Shah NN, Savani BN, Shaw BE, Abraham AA, Ahmed IA, et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transpl. 2015;50:1013\u201323.","journal-title":"Bone Marrow Transpl"},{"key":"1693_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2307\/2530374","volume":"34","author":"RL Prentice","year":"1978","unstructured":"Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34:541\u201354.","journal-title":"Biometrics"},{"key":"1693_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141\u201354.","journal-title":"Ann Stat"},{"key":"1693_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"1693_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.0006-341X.2001.00114.x","volume":"57","author":"G Heinze","year":"2001","unstructured":"Heinze G, Schemper M. A solution to the problem of monotone likelihood in Cox regression. Biometrics. 2001;57:114\u20139.","journal-title":"Biometrics"},{"key":"1693_CR21","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","volume":"113","author":"JD Rizzo","year":"2009","unstructured":"Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113:1175\u201383.","journal-title":"Blood"},{"key":"1693_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1182\/blood-2010-07-294629","volume":"117","author":"NS Majhail","year":"2011","unstructured":"Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011;117:316\u201322.","journal-title":"Blood"},{"key":"1693_CR23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJM199703273361301","volume":"336","author":"RE Curtis","year":"1997","unstructured":"Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, et al. Solid cancers after bone marrow transplantation. N. Engl J Med. 1997;336:897\u2013904.","journal-title":"N. Engl J Med"},{"key":"1693_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.2001.19.2.464","volume":"19","author":"S Bhatia","year":"2001","unstructured":"Bhatia S, Louie AD, Bhatia R, O\u2019Donnell MR, Fung H, Kashyap A, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001;19:464\u201371.","journal-title":"J Clin Oncol"},{"key":"1693_CR25","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1200\/JCO.2006.08.9276","volume":"25","author":"A Cohen","year":"2007","unstructured":"Cohen A, Rovelli A, Merlo DF, van Lint MT, Lanino E, Bresters D, et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol. 2007;25:2449\u201354.","journal-title":"J Clin Oncol"},{"key":"1693_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/leu.2014.203","volume":"29","author":"AS Nelson","year":"2015","unstructured":"Nelson AS, Ashton LJ, Vajdic CM, Le Marsney RE, Daniels B, Nivison-Smith I, et al. Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy. Leukemia. 2015;29:441\u20137.","journal-title":"Leukemia"},{"key":"1693_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3857\/roj.2018.00290","volume":"36","author":"CB Dracham","year":"2018","unstructured":"Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J. 2018;36:85\u201394.","journal-title":"Radiat Oncol J"},{"key":"1693_CR28","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.4149\/neo_2020_200214N131","volume":"67","author":"P Keslova","year":"2020","unstructured":"Keslova P, Formankova R, Riha P, Sramkova L, Snajderova M, Malinova B, et al. Total body irradiation is a crucial risk factor for developing secondary carcinomas after allogeneic hematopoietic stem cell transplantation in childhood. Neoplasma. 2020;67:1164\u20139.","journal-title":"Neoplasma"},{"key":"1693_CR29","doi-asserted-by":"crossref","unstructured":"Gunduz M, Ozen M, Sahin U, Toprak SK, Civriz Bozdag S, Kurt Yuksel M, et al. Subsequent malignancies after allogeneic hematopoietic stem cell transplantation. Clin Transplant. 2017;31:e12987.","DOI":"10.1111\/ctr.12987"},{"key":"1693_CR30","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1182\/blood-2004-07-2683","volume":"105","author":"J Libura","year":"2005","unstructured":"Libura J, Slater DJ, Felix CA, Richardson C. Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion. Blood. 2005;105:2124\u201331.","journal-title":"Blood"},{"key":"1693_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/pbc.20380","volume":"45","author":"MC Le Deley","year":"2005","unstructured":"Le Deley MC, Vassal G, Taibi A, Shamsaldin A, Leblanc T, Hartmann O. High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr Blood Cancer. 2005;45:25\u201331.","journal-title":"Pediatr Blood Cancer"},{"key":"1693_CR32","first-page":"969","volume":"90","author":"B Hertenstein","year":"2005","unstructured":"Hertenstein B, Hambach L, Bacigalupo A, Schmitz N, McCann S, Slavin S, et al. Development of leukemia in donor cells after allogeneic stem cell transplantation-a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2005;90:969\u201375.","journal-title":"Haematologica"},{"key":"1693_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","volume":"20","author":"S Mendez-Ferrer","year":"2020","unstructured":"Mendez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, et al. Bone marrow niches in haematological malignancies. Nat Rev Cancer. 2020;20:285\u201398.","journal-title":"Nat Rev Cancer"},{"key":"1693_CR34","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1001\/jama.297.11.1207","volume":"297","author":"N Hijiya","year":"2007","unstructured":"Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007;297:1207\u201315.","journal-title":"JAMA"},{"key":"1693_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/pbc.23083","volume":"57","author":"M Renard","year":"2011","unstructured":"Renard M, Suciu S, Bertrand Y, Uyttebroeck A, Ferster A, van der Werff Ten Bosch J, et al. Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: low incidence of CNS tumours. Pediatr Blood Cancer. 2011;57:119\u201325.","journal-title":"Pediatr Blood Cancer"},{"key":"1693_CR36","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1182\/blood.2018874115","volume":"133","author":"KS Baker","year":"2019","unstructured":"Baker KS, Leisenring WM, Goodman PJ, Ermoian RP, Flowers ME, Schoch G, et al. Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. Blood. 2019;133:2790\u20139.","journal-title":"Blood"},{"key":"1693_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.radonc.2020.10.032","volume":"155","author":"BAW Hoeben","year":"2021","unstructured":"Hoeben BAW, Pazos M, Albert MH, Seravalli E, Bosman ME, Losert C, et al. Towards homogenization of total body irradiation practices in pediatric patients across SIOPE affiliated centers. A survey by the SIOPE radiation oncology working group. Radiother Oncol. 2021;155:113\u20139.","journal-title":"Radiother Oncol"},{"key":"1693_CR38","doi-asserted-by":"publisher","first-page":"e477","DOI":"10.1016\/S1470-2045(20)30342-9","volume":"21","author":"JYC Wong","year":"2020","unstructured":"Wong JYC, Filippi AR, Scorsetti M, Hui S, Muren LP, Mancosu P. Total marrow and total lymphoid irradiation in bone marrow transplantation for acute leukaemia. Lancet Oncol. 2020;21:e477\u201387.","journal-title":"Lancet Oncol"},{"key":"1693_CR39","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.bbmt.2017.01.067","volume":"23","author":"A Stein","year":"2017","unstructured":"Stein A, Palmer J, Tsai NC, Al Malki MM, Aldoss I, Ali H, et al. Phase I Trial of total marrow and lymphoid irradiation transplantation conditioning in patients with relapsed\/refractory acute leukemia. Biol Blood Marrow Transpl. 2017;23:618\u201324.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1693_CR40","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s12094-019-02205-9","volume":"22","author":"A Ocanto","year":"2020","unstructured":"Ocanto A, Escribano A, Glaria L, Rodriguez I, Ferrer C, Huertas C, et al. TLI in pediatric patients. Clin Transl Oncol. 2020;22:884\u201391.","journal-title":"Clin Transl Oncol"},{"key":"1693_CR41","doi-asserted-by":"crossref","unstructured":"Hoeben BAW, Pazos M, Seravalli E, Bosman ME, Losert C, Albert MH, et al. ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children. Radiother Oncol. 2022;173:119\u201333.","DOI":"10.1016\/j.radonc.2022.05.027"},{"key":"1693_CR42","doi-asserted-by":"publisher","first-page":"775485","DOI":"10.3389\/fped.2021.775485","volume":"9","author":"K Ben Hassine","year":"2021","unstructured":"Ben Hassine K, Powys M, Svec P, Pozdechova M, Versluys B, Ansari M, et al. Total body irradiation forever? Optimising chemotherapeutic options for irradiation-free conditioning for paediatric acute lymphoblastic leukaemia. Front Pediatr. 2021;9:775485.","journal-title":"Front Pediatr"},{"key":"1693_CR43","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843\u201354.","journal-title":"JAMA"},{"key":"1693_CR44","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4:5414\u201324.","journal-title":"Blood Adv"},{"key":"1693_CR45","doi-asserted-by":"publisher","first-page":"784024","DOI":"10.3389\/fped.2021.784024","volume":"9","author":"J Buechner","year":"2021","unstructured":"Buechner J, Caruana I, Kunkele A, Rives S, Vettenranta K, Bader P, et al. Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant? Front Pediatr. 2021;9:784024.","journal-title":"Front Pediatr"},{"key":"1693_CR46","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.bbmt.2018.03.002","volume":"24","author":"I Yaniv","year":"2018","unstructured":"Yaniv I, Krauss AC, Beohou E, Dalissier A, Corbacioglu S, Zecca M, et al. Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study. Biol Blood Marrow Transpl. 2018;24:1629\u201342.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1693_CR47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.14965","volume":"180","author":"M Kuhlen","year":"2018","unstructured":"Kuhlen M, Willasch AM, Dalle JH, Wachowiak J, Yaniv I, Ifversen M, et al. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003\/2007 trial. Br J Haematol. 2018;180:82\u20139.","journal-title":"Br J Haematol"},{"key":"1693_CR48","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1182\/blood.V78.10.2780.2780","volume":"78","author":"R Dopfer","year":"1991","unstructured":"Dopfer R, Henze G, Bender-Gotze C, Ebell W, Ehninger G, Friedrich W, et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Blood. 1991;78:2780\u20134.","journal-title":"Blood"},{"key":"1693_CR49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2018.07.006","volume":"102","author":"R Haupt","year":"2018","unstructured":"Haupt R, Essiaf S, Dellacasa C, Ronckers CM, Caruso S, Sugden E, et al. The \u2018Survivorship Passport\u2019 for childhood cancer survivors. Eur J Cancer. 2018;102:69\u201381.","journal-title":"Eur J Cancer"},{"key":"1693_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5581\/1516-8484.20120032","volume":"34","author":"NS Majhail","year":"2012","unstructured":"Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter. 2012;34:109\u201333.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"1693_CR51","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/bmt.2016.95","volume":"51","author":"CA Clark","year":"2016","unstructured":"Clark CA, Savani M, Mohty M, Savani BN. What do we need to know about allogeneic hematopoietic stem cell transplant survivors? Bone Marrow Transpl. 2016;51:1025\u201331.","journal-title":"Bone Marrow Transpl"},{"key":"1693_CR52","doi-asserted-by":"crossref","unstructured":"Versluijs B, De Koning CCH, Lankester AC, Nierkens S, Kollen WJ, Bresters D, et al. Clofarabine-fludarabinebusulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen. Blood Adv. 2022;6:1719\u201330.","DOI":"10.1182\/bloodadvances.2021005224"},{"key":"1693_CR53","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00268-018-4479-z","volume":"42","author":"Y Ito","year":"2018","unstructured":"Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A. Overall survival of papillary thyroid carcinoma patients: a single-institution long-term follow-up of 5897 patients. World J Surg. 2018;42:615\u201322.","journal-title":"World J Surg"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01693-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01693-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01693-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T04:03:24Z","timestamp":1667102604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01693-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1693"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01693-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"20 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AC, AS, AW, BB, BG, BS, BSL, CFC, DS, EG, HD, IM, JG, KK, MS, OB, PGS, PL, RB, SC, TG and UP have no conflict of interest to declare. AE has received conference support from Gilead. JSK has a consulting\/advisory role with Bluebird Bio and has received honoraria from Jazz Pharmaceuticals. PB declares research support from Neovii, Riemser and Medac, advisory role for Novartis, Cellgene, Amgen, Medac and Servier, speakers bureau for Miltenyi, Jazz, Riemser, Novartis, Amgen and holds a patent with and receives royalties from Medac. RM has a consulting\/advisory role with Bluebird Bio, Vertex Pharmaceuticals, Bellicum Pharmaceuticals, Novartis and has received travel\/accommodation support by Jazz Pharmaceuticals. CP received funding from Amgen, Neovii, Medac, Novartis, Pfizer, Jazz and Riemser. MHA has a consulting\/advisory role with Orchard Therapeutics, Bluebird Bio, Bellicum Pharmaceuticals, CSL, Biotest and has received travel\/accommodation support by octapharma, Medac, Neovii and Jazz Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}